PMID- 33309581
OWN - NLM
STAT- MEDLINE
DCOM- 20210917
LR  - 20210917
IS  - 2213-1787 (Electronic)
IS  - 2213-1779 (Linking)
VI  - 9
IP  - 2
DP  - 2021 Feb
TI  - Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in 
      Patients With Heart Failure With and Without Diabetes.
PG  - 137-145
LID - S2213-1779(20)30578-3 [pii]
LID - 10.1016/j.jchf.2020.09.014 [doi]
AB  - OBJECTIVE: This study sought to determine whether patients with heart failure and 
      reduced ejection fraction (HFrEF) with type 2 diabetes mellitus (T2DM) have 
      similar reverse cardiac remodeling with sacubitril/valsartan as patients without 
      T2DM. BACKGROUND: Sacubitril/valsartan promotes reverse cardiac remodeling and 
      improves outcomes in patients with HFrEF. Patients with HFrEF with T2DM have 
      worse prognosis than those without T2DM. METHODS: In this post hoc analysis of 
      PROVE-HF (Prospective Study of Biomarkers, Symptom Improvement, and Ventricular 
      Remodeling During Sacubitril/Valsartan Therapy for Heart Failure), we examined 
      changes in N-terminal pro-b-type natriuretic peptide (NT-proBNP), measures of 
      cardiac remodeling, and Kansas City Cardiomyopathy Questionnaire Overall Summary 
      (KCCQ-OS) scores from baseline to 12 months following initiation of 
      sacubitril/valsartan between patients with HFrEF with and without T2DM. Using 
      latent growth curve modeling, we evaluated the longitudinal association between 
      changes in NT-proBNP, left ventricular ejection fraction, and KCCQ-OS. RESULTS: 
      Among 794 patients enrolled, 361 (45.5%) had T2DM. NT-proBNP concentrations were 
      modestly higher at baseline among patients with T2DM but were reduced after 
      initiation of sacubitril/valsartan. Cross-sectional improvement was observed in 
      left ventricular ejection fraction (T2DM: 28.3% at baseline and 37% at 12 months 
      vs. non-T2DM: 28.1% at baseline and 38.3% at 12 months) and KCCQ-OS (T2DM: 71 at 
      baseline and 83 at 12 months vs. non-T2DM: 76 at baseline and 88 at 12 months). 
      Similar changes were also observed for other echocardiographic measures. In 
      longitudinal analyses, the average NT-proBNP change was similar in patients with 
      T2DM (-5.6% vs. -7.1% per 90-day interval; p = 0.64), whereas improvements in 
      KCCQ-OS scores were slightly smaller (2.1 vs. 3.46 per 90-day interval; 
      p = 0.07). CONCLUSIONS: Sacubitril/valsartan favorably affects natriuretic 
      peptide levels, reverse cardiac remodeling, and health status in patients with 
      HFrEF with and without T2DM. (Effects of Sacubitril/Valsartan Therapy on 
      Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183).
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Khan, Muhammad Shahzeb
AU  - Khan MS
AD  - University of Mississippi, Jackson, Mississippi, USA.
FAU - Felker, G Michael
AU  - Felker GM
AD  - Duke University Medical Center and Duke Clinical Research Institute, Durham, 
      North Carolina, USA.
FAU - Pina, Ileana L
AU  - Pina IL
AD  - Detroit Medical Center, Detroit, Michigan, USA.
FAU - Camacho, Alexander
AU  - Camacho A
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - Bapat, Devavrat
AU  - Bapat D
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - Ibrahim, Nasrien E
AU  - Ibrahim NE
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - Maisel, Alan S
AU  - Maisel AS
AD  - University of California-San Diego School of Medicine, San Diego, California, 
      USA.
FAU - Prescott, Margaret F
AU  - Prescott MF
AD  - Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
FAU - Ward, Jonathan H
AU  - Ward JH
AD  - Novartis Pharmaceuticals, East Hanover, New Jersey, USA.
FAU - Solomon, Scott D
AU  - Solomon SD
AD  - Brigham and Women's Hospital, Boston, Massachusetts, USA.
FAU - Januzzi, James L
AU  - Januzzi JL
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - Butler, Javed
AU  - Butler J
AD  - University of Mississippi, Jackson, Mississippi, USA. Electronic address: 
      jbutler4@umc.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT02887183
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201209
PL  - United States
TA  - JACC Heart Fail
JT  - JACC. Heart failure
JID - 101598241
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 80M03YXJ7I (Valsartan)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aminobutyrates
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Biphenyl Compounds
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Drug Combinations
MH  - *Heart Failure/complications/drug therapy
MH  - Humans
MH  - Prospective Studies
MH  - Stroke Volume
MH  - Valsartan/therapeutic use
MH  - Ventricular Function, Left
MH  - Ventricular Remodeling
OTO - NOTNLM
OT  - NT-proBNP
OT  - cardiac remodeling
OT  - diabetes
OT  - heart failure
OT  - sacubitril/valsartan
COIS- Funding Support and Author Disclosures Dr. Felker has received personal fees from 
      Novartis, Bristol Myers Squibb, Medtronic, Innolife, EBR Systems, Arena, Abbott, 
      Alnylam, SC Pharma, Rocket, Sphingotec, LivaNova, Cardionomic, Relypsa, V-Wave, 
      and MyoKardia; grants from the National Heart, Lung, and Blood Institute, 
      American Heart Association, and Merck; and grants and personal fees from Amgen, 
      Cytokinetics, and Roche Diagnostics. Dr. Pina has received consulting income from 
      Relypsa and Novartis. Dr. Ibrahim is funded in part by the Dennis and Marilyn 
      Barry Fund in Cardiovascular Research and has received honoraria from Novartis 
      and Roche Diagnostics. Dr. Maisel has received consulting income from Abbott 
      Vascular, Ortho Clinical Diagnostics, and Novartis. Drs. Prescott and Ward are 
      employees of Novartis Pharmaceuticals Inc. Dr. Solomon has received research 
      grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol Myers 
      Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lilly, 
      Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, 
      Respicardia, Sanofi Pasteur, and Theracos; and has consulted for Abbott, Akros, 
      Alnylam, Amgen, Arena, AstraZeneca, Bayer, Bristol Myers Squibb, Cardior, 
      Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GlaxoSmithKline, 
      Ironwood, Lilly, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum 
      Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Tenaya, 
      Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, and Moderna. Dr. Januzzi reported 
      receiving personal fees from the American College of Cardiology, Pfizer, Merck, 
      AbbVie, Amgen, Boehringer Ingelheim, and Takeda; grants and personal fees from 
      Novartis, Roche, Abbott, and Janssen; and grants from Singulex and Prevencio. Dr. 
      Butler serves as a consultant for Abbott, Adrenomed, Amgen, Array, AstraZeneca, 
      Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, 
      Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, 
      Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Limited, and Vifor. All other 
      authors have reported that they have no relationships relevant to the contents of 
      this paper to disclose.
EDAT- 2020/12/15 06:00
MHDA- 2021/09/18 06:00
CRDT- 2020/12/14 10:15
PHST- 2020/07/15 00:00 [received]
PHST- 2020/09/23 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/12/15 06:00 [pubmed]
PHST- 2021/09/18 06:00 [medline]
PHST- 2020/12/14 10:15 [entrez]
AID - S2213-1779(20)30578-3 [pii]
AID - 10.1016/j.jchf.2020.09.014 [doi]
PST - ppublish
SO  - JACC Heart Fail. 2021 Feb;9(2):137-145. doi: 10.1016/j.jchf.2020.09.014. Epub 
      2020 Dec 9.